T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure

Journal of Molecular Medicine

Volumn 83, Issue 11, 2005, Pages 904-916

  Bakalash, Sharon ^a   Shlomo, Gil Ben ^b   Aloni, Eyal ^c   Shaked, Iftach ^a   Wheeler, Larry ^d   Ofri, Ron ^b   Schwartz, Michal ^a,e  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c KAPLAN MEDICAL CENTER   (Israel)

^d ALLERGAN INC   (United States)

^e Department of Neuroimmunology ^*  (Israel)

Author keywords

Glaucoma; Neurodegenerative diseases; Neuroprotection; Protective autoimmunity

Indexed keywords

ADJUVANT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGEN; GLATIRAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL LOSS; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; ELECTRORETINOGRAPHY; EYE; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NEWBORN; NONHUMAN; RAT; RETINA GANGLION CELL; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APOPTOSIS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; INTRAOCULAR PRESSURE; LYMPHOCYTE ACTIVATION; MALE; OPHTHALMIC SOLUTIONS; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; REPRESSOR PROTEINS; RETINAL GANGLION CELLS; T-LYMPHOCYTES; TIME FACTORS; VACCINATION;

EID: 27744603039     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-005-0689-6     Document Type: Article

References (66)

1. Schwartz M, Belkin M, Yoles E, Solomon A (1996) Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J Glaucoma 5:427-432
2. Kaufman PL, Gabelt B, Tian B, Liu X (1999) Advances in glaucoma diagnosis and therapy for the next millennium: new drugs for trabecular and uveoscleral outflow. Semin Ophthalmol 14:130-143
3. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA (1996) Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 114:299-305
4. Weinreb RN (2001) Lowering intraocular pressure to minimize glaucoma damage. J Glaucoma 10(5 Suppl 1):S76-S77
5. Yoles E, Schwartz M (1998) Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol 153:1-7
6. Chidlow G, Osborne NN (2003) Rat retinal ganglion cell loss caused by kainate, NMDA and ischemia correlates with a reduction in mRNA and protein of Thy-1 and neurofilament light. Brain Res 963:298-306
7. Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, Leibowitz-Amit R, Pevsner E, Akselrod S, Neeman M, Cohen IR, Schwartz M (2000) Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci 20:6421-6430
8. Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, Schwartz M (2001) Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci 21:4564-4571
9. Mizrahi T, Hauben E, Schwartz M (2002) The tissue-specific self-pathogen is the protective self-antigen: the case of uveitis. J Immunol 169:5971-5977
10. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, Schwartz M (2001) Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 98:3398-3403
11. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, Kuchroo V, Cohen IR, Weiner H, Schwartz M (2001) Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 21:3740-3748
12. Muhallab S, Lundberg C, Gielen AW, Lidman O, Svenningsson A, Piehl F, Olsson T (2002) Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand J Immunol 55:264-273
13. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S, Svenningsson A, Linda H, van Der Meide PH, Cullheim S, Olsson T, Piehl F (2000) Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 20:5283-5291
14. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M (2003) Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Investig Ophthalmol Vis Sci 44:3374-3381
15. Butovsky O, Hauben E, Schwartz M (2001) Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7-2 (CD86) and prevention of cyst formation. FASEB J 15:1065-1067
16. Bakalash S, Kipnis J, Yoles E, Schwartz M (2002) Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Investig Ophthalmol Vis Sci 43:2648-2653
17. Fisher J, Levkovitch-Verbin H, Schori H, Yoles E, Butovsky O, Kaye JF, Ben-Nun A, Schwartz M (2001) Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies. J Neurosci 21:136-142
18. Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, Smirnov I, Steinman L, Schwartz M (2001) Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest 108:591-599
19. + regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci U S A 99:15620-15625
20. Shaked I, Porat Z, Gersner R, Kipnis J, Schwartz M (2004) Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. J Neuroimmunol 146:84-93
21. Kipnis J, Schwartz M (2002) Dual action of glatiramer acetate (Cop-1) as a treatment for autoimmune diseases and a vaccine for protective autoimmunity after CNS injury. Trends Mol Med 8:319-323
22. Hafler DA (2002) Degeneracy, as opposed to specificity, in immunotherapy. J Clin Invest 109:581-584
23. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, Tomov TL, Yoles E, Kipnis J, Schori H, Reuter A, Ludolph A, Schwartz M (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: implications for ALS. Proc Natl Acad Sci U S A 100:4790-4795
24. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101:9435-9440
25. Jia L, Cepurna WO, Johnson EC, Morrison JC (2000) Patterns of intraocular pressure elevation after aqueous humor outflow obstruction in rats. Investig Ophthalmol Vis Sci 41:1380-1385
26. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, Cohen IR, Schwartz M (2000) T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 97:7446-7451
27. Remtulla S, Hallett PE (1985) A schematic eye for the mouse, and comparisons with the rat. Vision Res 25:21-31
28. Hughes A (1977) The refractive state of the rat eye. Vision Res 17:927-939
29. Onofrj M, Harnois C, Bodis-Wollner I (1985) The hemispheric distribution of the transient rat VEP: a comparison of flash and pattern stimulation. Exp Brain Res 59:427-433
30. Pizzorusso T, Fagiolini M, Porciatti V, Maffei L (1997) Temporal aspects of contrast visual evoked potentials in the pigmented rat: effect of dark rearing. Vision Res 37:389-395
31. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5:49-55
32. Corradin SB, Mauel J, Donini SD, Quattrocchi E, Ricciardi-Castagnoli P (1993) Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 7:255-262
33. Shaked I, Tchorsh D, Gersner R, Meiri G, Mordechay S, Xiao X, Hart RP, Schwartz M (2005) Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem 92: 997-1009
34. Swanson RA, Liu J, Miller JW, Rothstein JD, Farrell K, Stein BA, Longuemare MC (1997) Neuronal regulation of glutamate transporter subtype expression in astrocytes. J Neurosci 17:932-940
35. Kipnis J, Nevo U, Panikashvili D, Alexanderovich A, Yoles E, Akselrod S, Shohami E, Schwartz M (2003) Therapeutic vaccination for closed head injury. J Neurotrauma 20:559-569
36. Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M (1999) Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J 13:1207-1217
37. Alessandri B, Bullock R (1998) Glutamate and its receptors in the pathophysiology of brain and spinal cord injuries. Prog Brain Res 116:303-330
38. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634
39. Berardi N, Domenici L, Gravina A, Maffei L (1990) Pattern ERG in rats following section of the optic nerve. Exp Brain Res 79:539-546
40. Domenici L, Gravina A, Berardi N, Maffei L (1991) Different effects of intracranial and intraorbital section of the optic nerve on the functional responses of rat retinal ganglion cells. Exp Brain Res 86:579-584
41. Hecht KA, Straus H, Denny M, Taylor F, Garrett M (1997) Glaucoma. American Academy of Ophthalmology, San Francisco, p 155
42. AsgTAGIS (1994) The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 15:299-325
43. AsgTAGIS (1994) The Advanced Glaucoma Intervention Study (AGIS): 2. Visual field test scoring and reliability. Ophthalmology 101:1445-1455
44. AsgTAGIS (1998) The Advanced Glaucoma Intervention Study (AGIS): 3. Baseline characteristics of black and white patients. Ophthalmology 105:1137-1145
45. AsgTAGIS (2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429-440
46. Schwartz M, Yoles E (2000) Neuroprotection: a new treatment modality for glaucoma? Curr Opin Ophthalmol 11:107-111
47. Schwartz M, Shaked I, Fisher J, Mizrahi T, Schori H (2003) Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 26:297-302
48. Hare WA, WoldeMussie E, Weinreb RN, Ton H, Ruiz G, Wijono M, Feldmann B, Zangwill L, Wheeler L (2004) Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Investig Ophthalmol Vis Sci 45:2640-2651
49. Neufeld AH, Kawai S, Das S, Vora S, Gachie E, Connor JR, Manning PT (2002) Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase. Exp Eye Res 75:521-528
50. Hickey WF, Hsu BL, Kimura H (1991) T-lymphocyte entry into the central nervous system. J Neurosci Res 28:254-260
51. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, Schwartz M (2000) Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Auto immun 15:331-345
52. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R (2002) Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125:2381-2391
53. Fiorentini A, Maffei L, Pirchio M, Spinelli D, Porciatti V (1981) The ERG in response to alternating gratings in patients with diseases of the peripheral visual pathway. Investig Ophthalmol Vis Sci 21:490-493
54. Korth M (1997) The value of electrophysiological testing in glaucomatous diseases. J Glaucoma 6:331-343
55. Marx MS, Podos SM, Bodis-Wollner I, Howard-Williams JR, Siegel MJ, Teitelbaum CS, Maclin EL, Severin C (1986) Flash and pattern electroretinograms in normal and laser-induced glaucomatous primate eyes. Investig Ophthalmol Vis Sci 27:378-386
56. Marx MS, Podos SM, Bodis-Wollner I, Lee PY, Wang RF, Severin C (1988) Signs of early damage in glaucomatous monkey eyes: low spatial frequency losses in the pattern ERG and VEP. Exp Eye Res 46:173-184
57. Ofri R, Dawson WW, Foli K, Gelatt KN (1993) Chronic ocular hypertension alters local retinal responsiveness. Br J Ophthalmol 77:502-508
58. Ofri R, Dawson WW, Foli K, Gelatt KN (1993) Primary open-angle glaucoma alters retinal recovery from a thiobarbiturate: spatial frequency dependence. Exp Eye Res 56:481-488
59. Swindale NV, Fendick MG, Drance SM, Graham SL, Hnik P (1996) Contrast sensitivity for flickering and static letters and visual acuity at isoluminance in glaucoma. J Glaucoma 5:156-169
60. Towle VL, Moskowitz A, Sokol S, Schwartz B (1983) The visual evoked potential in glaucoma and ocular hypertension: effects of check size, field size, and stimulation rate. Investig Ophthalmol Vis Sci 24:175-183
61. Bodis-Wollner I (1989) Electrophysiological and psychophysical testing of vision in glaucoma. Surv Ophthalmol 33 (Suppl):301-307
62. Brooks DE, Komaromy AM, Kallberg ME (1999) Comparative optic nerve physiology: implications for glaucoma, neuroprotection, and neuroregeneration. Vet Ophthalmol 2:13-25
63. Trible JR, Anderson DR (1997) Factors associated with intraocular pressure-induced acute visual field depression. Arch Ophthalmol 115:1523-1527
64. Anderson DR, Cynader MS (1997) Glaucomatous optic nerve cupping as an optic neuropathy. Clin Neurosci 4:274-278
65. Guo L, Fitzke FW, Cordeiro MF (2004) Selective large-cell retinal ganglion cell apoptosis in early glaucomatous disease models. Investig Ophthalmol Vis Sci ARVO Abstr 2153
66. Fortune B, Bui BV, Morrison JC, Johnson EC, Dong J, Cepurna WO, Jia L, Barber S, Cioffi GA (2004) Selective ganglion cell functional loss in rats with experimental glaucoma. Investig Ophthalmol Vis Sci 45:1854-1862